Vox Markets Logo

Neil Clark of Destiny Pharma discusses new research programme and progress on lead clinical assets

09:37, 6th July 2022
AudioBoom | https://audioboom.com/posts/8115858-neil-clark-of-destiny-pharma-discusses-new-research-programme-and-progress-on-lead-clinical-assets

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Neil Clark, CEO of Destiny Pharma #DEST Follow | DEST discusses the start of a new XF-73 research programme as a preventive medicine to alleviate suffering from Oral Mucositis in patients receiving cancer treatment by testing its efficacy in the gold-standard model of OM & also provides an update on the progress of their lead clinical assets.

Highlights

The potential utility of XF-73 in this indication is due to the long-recognised association between the development of OM and changes in the oral microbiome. The unique antimicrobial properties of XF‑73 have already been demonstrated in Phase 2 clinical trials. As well as having fast-acting antimicrobial activity and a novel mechanism of action, XF-73 has an excellent safety profile and a lack of systemic exposure which means that it is ideally suited for development as an innovative oral formulation to reduce the severity of OM.

Inflammation of the mucosa (mucositis) is considered one of the most serious non-hematological complications of cancer treatment and a common dose-limiting complication of high-dose radiotherapy and chemotherapy in cancer and bone marrow transplant patients of all ages. Globally, more than two million cancer patients suffer from this condition each year. The global OM market was estimated at $2.2b in 2018.

To read the full RNS click here

 

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist